Picard Medical, INC. 8-K Filing

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share PMI The NYSE American, LL

Filing Documents

• picardmedical_8k.htm (8-K) — 31KB
• picardmedical_ex99-1.htm (EX-99.1) — 10KB
• ex99-1_001.jpg (GRAPHIC) — 27KB
• 0001829126-25-009304.txt ( ) — 243KB
• pmi-20251119.xsd (EX-101.SCH) — 3KB
• pmi-20251119_lab.xml (EX-101.LAB) — 33KB
• pmi-20251119_pre.xml (EX-101.PRE) — 22KB
• picardmedical_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On November 19, 2025, Picard Medical, Inc. issued a press release announcing that SynCardia Systems LLC, its wholly owned subsidiary, completed the first in vivo implantations of the Emperor Total Artificial Heart. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this report and the exhibits attached hereto shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Picard Medical, Inc. Press Release dated November 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Picard Medical, Inc. By: /s/ Patrick NJ Schnegelsberg Name: Patrick NJ Schnegelsberg Title: Chief Executive Officer Dated: November 19, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR